Clinical trial
A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly…
NCT00479648 · Seqirus, Industry · Completed
Key facts
| NCT number | NCT00479648 |
|---|---|
| Title | A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants |
| Official title | A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years) |
| Lead sponsor | Seqirus, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | CSL412, Inactivated trivalent influenza vaccine |
| Enrollment | 612 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | May 28, 2007 |
| Last update posted | Jul 19, 2016 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: